Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. trimmed its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 16.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,982 shares of the biopharmaceutical company’s stock after selling 7,668 shares during the period. Fox Run Management L.L.C.’s holdings in Catalyst Pharmaceuticals were worth $793,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Rhumbline Advisers lifted its stake in Catalyst Pharmaceuticals by 0.3% during the 4th quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company’s stock valued at $6,518,000 after acquiring an additional 952 shares during the period. Handelsbanken Fonder AB lifted its stake in Catalyst Pharmaceuticals by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company’s stock valued at $740,000 after acquiring an additional 1,000 shares during the period. Xponance Inc. lifted its stake in Catalyst Pharmaceuticals by 6.8% during the 4th quarter. Xponance Inc. now owns 18,763 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 1,189 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at approximately $27,000. Finally, Farther Finance Advisors LLC lifted its stake in shares of Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,495 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

CPRX has been the subject of several analyst reports. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Stephens reiterated an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Robert W. Baird boosted their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $32.29.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $24.23 on Monday. The firm has a fifty day moving average of $22.39 and a 200 day moving average of $21.63. The firm has a market cap of $2.94 billion, a PE ratio of 20.53, a PEG ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $24.64.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.